[Chemosensitivity assays for malignant gliomas].
Chemosensitivity assays including colony forming assay (CFA), MTT dye reduction assay (MTT assay) and thymidine incorporation assay (TIA) for cultured rat and human glioma cells were conducted to determine the correlation among them and the in vivo antitumor efficacy of anticancer drugs using rats implanted glioma cells. Cytotoxicity of various agents such as ACNU, ACR, CDDP, VCR or BLM, was estimated from the concentrations which caused 50% inhibition of the cell growth at the peak plasma concentration. The survival time of tumor bearing rats was assessed after ip treatment with these agents at their estimated clinical doses. This parameter was greater in the drugs that were shown to be highly sensitive in CFA and was consistent with the data for CFA. In the chemosensitivity assays, CFA closely correlated to MTT assay for all agents except VCR, but poorly so to TIA. The results in this study indicate that MTT assay seemed to be useful for determining the chemosensitivity of anticancer drugs and that chemosensitivity assay should be conducted depending on the nature of anticancer drug.
Sasaoka
N
N
Dept. of Neurological Surgery, Kagawa Medical School, Japan.
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001932:Brain Neoplasms / Q000473:pathology*; D002945:Cisplatin / Q000494:pharmacology; D004354:Drug Screening Assays, Antitumor / Q000379:methods; D005910:Glioma / Q000473:pathology*; D006801:Humans; D008297:Male; D015376:Nimustine / Q000494:pharmacology; D051381:Rats; D011916:Rats, Inbred F344; D014750:Vincristine / Q000494:pharmacology
D000970:Antineoplastic Agents; D015376:Nimustine; D014750:Vincristine; D002945:Cisplatin